Welcome
Support Centre
07 August 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Acute lymphoblastic leukaemia (ALL) trial XII (joint trial with Eastern Co-operative Oncology Group - E2993)
ISRCTN ISRCTN77346223
ClinicalTrials.gov identifier NCT00002514
Public title Acute lymphoblastic leukaemia (ALL) trial XII (joint trial with Eastern Co-operative Oncology Group - E2993)
Scientific title
Acronym UKALLXII
Serial number at source G8223452, MREC/02/2/84
Study hypothesis To compare effects of marrow ablative therapy using VP16 and total body irradiation followed by autologous bone marrow rescue (ABMT or Peripheral Stem Cell Rescue) with conventional consolidation and maintenance chemotherapy in adult patients between 15 and 55 years who have no HLA compatible donor. To examine (in a non-randomised study) differences in outcome in adult ALL in those patients who have an HLA compatible donor, who will be allocated allogeneic BMT vs. those with a donor randomised to autologous BMT or conventional chemotherapy. To compare the outcome of the above three treatments or matched unrelated donor BMT in patients with Philadelphia chromosome positive disease and to examine the efficacy of additional Interferon during maintenance chemotherapy or after BMT.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Leukaemia
Participants - inclusion criteria 1. Adult patients between 15 and 55 years with previously untreated ALL
2. Morphological proof of ALL
3. Diagnosis has been made from bone marrow morphology with greater than 25% lymphoblasts by the French-American-British (FAB) criteria
Participants - exclusion criteria 1. Prior malignancy for which chemotherapy or radiotherapy have been given
2. AML, MDS or other antecedent haematological disorder or lymphoid transformation of chronic myeloid leukaemia
3. Previously treated
4. Intercurrent life threatening disease
5. Pregnant or lactating
Anticipated start date 01/01/1993
Anticipated end date 30/09/2008
Status of trial Ongoing
Patient information material
Target number of participants 550
Interventions 1. Marrow ablative therapy using VP16 and total body irradiation followed by autologous bone marrow rescue (ABMT or Peripheral Stem Cell Rescue)
2. Conventional consolidation and maintenance chemotherapy
Primary outcome measure(s) Length of survival, relapse rates.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Medical Research Council
Trial website http://www.ctsu.ox.ac.uk/projects/leuk/ukallxii/new-4th-dec-2006/ukallxii-protocol-version-5-0.pdf
Publications 1. Results March 2007 in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstract&list_uids=16421910
2. Results July 2006 in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16556888
Contact name Professor  A  Goldstone
  Address University College Hospital
Gower Street
  City/town London
  Zip/Postcode WC1E 6AU
  Country United Kingdom
  Email
Sponsor Medical Research Council (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 25/10/2000
Last edited 02/04/2007
Date ISRCTN assigned 25/10/2000
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central